Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

n and our financial performance.

Our actual results may vary depending on a variety of factors, including:

  • the development of competitive generic versions of oral Vancocin;
  • our ability to successfully commercialize Cinryze;
  • our ability to receive regulatory approval for the use of Cinryze for the acute treatment of HAE;
  • the availability of third party payer reimbursement for Cinryze patients;
  • our ability to develop a clinical development program for maribavir;
  • approval of products which are currently marketed for other indications by other companies or new pharmaceuticals and technological advances to treat the conditions addressed by Vancocin or Cinryze;
  • fluctuations in wholesaler order patterns and inventory levels;
  • manufacturing, supply or distribution interruptions, including but not limited to our ability to acquire adequate supplies of Vancocin and Cinryze to meet demand for the product;
  • changes in prescribing or procedural practices of physicians, including off-label prescribing of products competitive with Vancocin and Cinryze;
  • the timing of regulatory submissions and approvals;
  • actions by the FDA, EMEA and the Internal Revenue Service or other government regulatory agencies;
  • decreases in the rate of infections for which Vancocin is prescribed or decreases in the sensitivity of the relevant bacteria to Vancocin;
  • an impairment of our intangible assets if our market capitalization remains less than our book value;
  • the timing and results of anticipated events in our clinical development programs; and
  • the timing and nature of potential business development activities related to our efforts to expand our current portfolio through in-licensing or other means of acquiring produ
    '/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... (PRWEB) July 24, 2014 Draper ... , is proud to announce that for 6 ... different countries will converge on the Draper University ... an intensive, experiential program focused on entrepreneurship, building ... selective school, currently running its sixth cohort, continues ...
(Date:7/24/2014)... As part of the long-term strategic ... MENA region during 2014 with potential global expansion. , ... with DZS to manage our clinical trials globally and ... of R&D and President of SBI pharmaceuticals MENA, Dr. ... with a focus on utilizing eClinical software and flexible ...
(Date:7/23/2014)... Emirates (UAE) (PRWEB) July 23, 2014 ... recently announced that its biobanking project, Provia ... Ph.D. to its growing Advisory Board. Scott Wolf ... pleased to have Dr. Vaught onboard with Provia’s ever-expanding ... and expertise that Provia’s management team brings to this ...
(Date:7/23/2014)... Physicists Sergei Filippov (MIPT and Russian Quantum Center ... Brno, Czech Republic, and the Institute of Physics ... preserve quantum entanglement of particles passing through an ... long distances. Details are provided in an article ... (see preprint). , Quantum entangled particles are ...
Breaking Biology Technology:Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 2Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 3SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 4Scientists find way to maintain quantum entanglement in amplified signals 2Scientists find way to maintain quantum entanglement in amplified signals 3Scientists find way to maintain quantum entanglement in amplified signals 4
... About 18 months ago, I sat with the product managers at ... were the $99 devices intended to be an entry-level digital organizer ... Shack and Target and wanted a simple product that delivered real ... a quick test drive, I leaned close to the product marketing ...
... Middleton, Wis. Standard Imaging , a Middleton-based ... treatment for cancer cardiology and other applications, has announced ... the assets acquired from the British Columbia-based company are ... with most electronic portal imaging devices (EPIDs). The PIPSpro ...
... The Wisconsin Alumni Research Foundation is suing ... computer memory chips, for allegedly using a patented technology developed ... in their semiconductors. , ,According to Andy Cohn, spokesman for ... is the same as previous legal actions against Sony ...
Cached Biology Technology:The Palm to "de-Zire" 2The Palm to "de-Zire" 3Standard Imaging acquires Canadian PIPSpro radiation treatment technologies 2WARF sues Samsung over computer chip technology license agreement 2
(Date:7/23/2014)... July 24, 2014 Pfenex Inc. (NYSE MKT: PFNX) ... 8,333,333 shares of its common stock at a price to ... granted the underwriters a 30-day option to purchase up to ... offering price. The shares are expected to begin trading on ... "PFNX". William Blair & Company, L.L.C. ...
(Date:7/23/2014)... The U.S. Environmental Protection Agency (EPA) today ... the University of Massachusetts Amherst School of Public ... three-year, $700,000 Science to Achieve Results (STAR) grant ... by Native subsistence hunters in subarctic North America ... exposure and to provide culturally-relevant recommendations for mitigation. ...
(Date:7/23/2014)... State University shows that urban "heat islands" are slowly ... factor is that researchers have found warmer temperatures increase ... insect a significant tree pest by 300 ... adult gloomy scales on urban trees. , "We,d been ... scale in cities, and now we know why," says ...
Breaking Biology News(10 mins):Pfenex Inc. Announces Pricing Of Initial Public Offering 2Studying impacts of indoor air pollution on tribal communities 2Studying impacts of indoor air pollution on tribal communities 3Urban heat boosts some pest populations 200-fold, killing red maples 2Urban heat boosts some pest populations 200-fold, killing red maples 3
... lot of variables come into play when selecting a site ... as wildlife needs, species and vegetation uniqueness, and costs to ... of Illinois researchers found that society and the environment ... are closer to people because people are more willing to ...
... Chemists and biologists have successfully demonstrated that specially synthesized ... a move that, they say, is a proof of ... In June 2008, University of Oregon chemist Shih-Yuan ... Chemical Society his lab,s synthesis of boron-nitrogen compounds ...
... Michigan are reporting the development of a powerful new probe ... in aging and disease. The probe works like a GPS ... could lead to new insights into disease processes and identify ... is scheduled for the Sept. 18 issue of ACS ...
Cached Biology News:Research recommends compromise when choosing conservation site 2Research recommends compromise when choosing conservation site 3Research recommends compromise when choosing conservation site 4Boron-based compounds trick a biomedical protein 2
SHEEP ANTI ESCHERICHIA COLI...
Recombinant Rat Leptin, CF...
2,4,6-Trinitrophenyl hapten is conjugated to Bovine Gamma Globulin (BGG) through lysine by amide bonds....
... • Holds 0.1 mL - 25 mL pipets ... pipets. Also accommodates most standard square or round pipet ... Has four compartments, each 76 mm W x 76 ... x 11 3/8 ins.). Overall dimensions: 89 mm W ...
Biology Products: